Prevention and treatment of the side effects of poly-ADP-ribose polymerase-1 inhibitors (iPARP) in breast and ovarian cancer

Q4 Medicine
Jean-Lionel Bagot MD (homeopath) , Jean-Philippe Wagner MD (specialist in oncology, radiotherapy)
{"title":"Prevention and treatment of the side effects of poly-ADP-ribose polymerase-1 inhibitors (iPARP) in breast and ovarian cancer","authors":"Jean-Lionel Bagot MD (homeopath) ,&nbsp;Jean-Philippe Wagner MD (specialist in oncology, radiotherapy)","doi":"10.1016/j.revhom.2021.07.001","DOIUrl":null,"url":null,"abstract":"<div><p><span><span>Poly-ADP-ribose polymerase inhibitors (iPARP) are a new class of targeted therapy which block the DNA repair mechanisms of </span>cancer cells<span><span> causing their apoptosis. They are mainly used in ovarian cancers to prevent a recurrence. The most common side effects are nausea and fatigue; the most serious are </span>blood toxicities. Prescribed over several months, supportive care is essential to improve </span></span>quality of life<span> and consequently compliance with iPARPs. In our experience, the use of homeopathy and of ultra-high dilutions of iPARP, reduces side effects and is a great help to patients. The lack of drug interactions makes it possible for them to be used safely. The low cost and very good tolerance of this supportive treatment make it very acceptable to patients. Preliminary clinical studies should be carried out to confirm our favourable clinical impression.</span></p></div>","PeriodicalId":39101,"journal":{"name":"Revue d''Homeopathie","volume":"12 3","pages":"Pages e36-e42"},"PeriodicalIF":0.0000,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revue d''Homeopathie","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1878973021001031","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Poly-ADP-ribose polymerase inhibitors (iPARP) are a new class of targeted therapy which block the DNA repair mechanisms of cancer cells causing their apoptosis. They are mainly used in ovarian cancers to prevent a recurrence. The most common side effects are nausea and fatigue; the most serious are blood toxicities. Prescribed over several months, supportive care is essential to improve quality of life and consequently compliance with iPARPs. In our experience, the use of homeopathy and of ultra-high dilutions of iPARP, reduces side effects and is a great help to patients. The lack of drug interactions makes it possible for them to be used safely. The low cost and very good tolerance of this supportive treatment make it very acceptable to patients. Preliminary clinical studies should be carried out to confirm our favourable clinical impression.

多聚adp核糖聚合酶-1抑制剂(iPARP)在乳腺癌和卵巢癌中的副反应的预防和治疗
poly - adp -核糖聚合酶抑制剂(iPARP)是一类阻断癌细胞DNA修复机制导致其凋亡的新型靶向治疗药物。它们主要用于卵巢癌,以防止复发。最常见的副作用是恶心和疲劳;最严重的是血液中毒。在几个月的处方中,支持性护理对改善生活质量和遵守iparp至关重要。根据我们的经验,使用顺势疗法和超高稀释iPARP,可以减少副作用,对患者有很大帮助。由于缺乏药物相互作用,它们可以安全使用。这种支持治疗的低成本和良好的耐受性使其非常容易被患者接受。初步的临床研究应进行,以证实我们的良好的临床印象。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Revue d''Homeopathie
Revue d''Homeopathie Medicine-Complementary and Alternative Medicine
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信